Rebekka Salonen

Rebekka Salonen

Auto-generated profile, based on publicly available information

Rebekka Salonen

Department of Pediatric Nephrology and Transplantation Children's Hospital Helsinki University Hospital and University of Helsinki Helsinki Finland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2023 in Pediatric Transplantation
Verified
Journal Article
Open access
RSRebekka Salonen
Rebekka Salonen
TJTimo Jahnukainen
Timo Jahnukainen
ANAtte Nikkilä
Atte Nikkilä
KEKira Endén
Kira Endén
Background: The present study aimed at investigating long‐term mortality of patients who underwent solid organ transplantation during childhood and at identifying their causes of death.Methods: A cohort of 233 pediatric solid organ transplant recipients who had a kidney, liver, or heart transplantation between 1982 and 2015 in Finland were studied. Year of birth‐, sex‐, and hometown‐matched controls (n = 1157) were identified using the Population Register Center registry. The Causes of Death Registry was utilized to identify the causes of death.Results: Among the transplant recipients, there were 60 (25.8%) deaths (median follow‐up 18.0 years, interquartile range of 11.0–23.0 years). Transplant recipients' risk of death was nearly 130‐fold higher than that of the controls (95% CI 51.9–1784.6). The 20‐year survival rates for kidney, liver, and heart recipients were 86.1% (95% CI 79.9%–92.3%), 58.5% (95% CI 46.2%–74.1%), and 61.4% (95% CI 48.1%–78.4%), respectively. The most common causes of death were cardiovascular diseases (23%), infections (22%), and malignancies (17%). There were no significant differences in survival based on sex or transplantation era.Conclusion: The late mortality is still significantly higher among pediatric solid organ recipients in comparison with controls. Cardiovascular complications, infections, and cancers are the main causes of late mortality for all studied transplant groups. These findings emphasize the cruciality of careful monitoring of pediatric transplant recipients in order to reduce long‐term mortality.

31 July 2025 in Clinical Transplantation
Verified
Journal Article
Open access
RSRebekka Salonen
Rebekka Salonen
KEKira Endén
Kira Endén
MKMikael Koskela
Mikael Koskela
KJKirsi Jahnukainen
Kirsi Jahnukainen
ANAtte Nikkilä
Atte Nikkilä
TJTimo Jahnukainen
Timo Jahnukainen
Background: Solid organ transplant (SOT) recipients are at risk for long‐term comorbidities and polypharmacy, potentially affecting quality of life. This study assessed the prevalence of chronic medication use among young adults following pediatric SOT. Methods: We included 215 individuals in Finland who underwent kidney ( n = 135), liver ( n = 41), or heart ( n = 39) transplantation before age 16 between 1982 and 2015 and were ≥18 years at follow‐up. Age, sex, and hometown‐matched controls ( n = 1067) were selected from the Finnish Population Information System. The analyses involved data on prescription drug purchases and reimbursements for chronic conditions derived from the registry of Social Insurance Institution, which covers all prescription medicine purchases in Finland. Results: The SOT recipients had an average of 1.53 reimbursed chronic conditions beyond immunosuppression (median follow‐up time:18.0 years, IQR 11.0–23.0), with the highest burden among kidney and lowest among liver transplant recipients. Compared to controls, SOT recipients had significantly more reimbursement for cardiovascular diseases, hormonal deficiencies, and epilepsy ( p < 0.001). Kidney transplant recipients had a significantly higher risk of cardiovascular‐related reimbursements than liver transplant group ( p < 0.001); no significant differences were observed between the transplant groups for other conditions. Conclusions: Young adults after pediatric SOT had an elevated need for chronic disease medications, with the highest burden observed in kidney transplant recipients and the lowest in liver transplant recipients. These findings highlight the importance of long‐term follow‐up and individualized transitional care to address multimorbidity and support quality of life.